Spots Global Cancer Trial Database for HRQoL Keratinocyte Carcinomas
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: HRQoL Keratinocyte Carcinomas
Official Title: HRQoL and Development of Health Utilities in Patients With Keratinocyte Carcinomas
Study ID: NCT04814953
Interventions
Study Description
Brief Summary: Rationale: Keratinocyte skin cancer is known to influence the HRQoL in a specific way. Derived utility values are required for cost-effectiveness analyses of new interventions. However there is no sensitive tool to capture HRQoL that translates into utilities available. Objective: To document the exact HRQoL in patients with in KC using the generic EQ-5D-5L questionnaire, as well as the TTO, 15D and the BaSQoL questionnaire, and to develop health utilities based on these tools. Study design: Longitudinal observational study (at time 0 and time 0 +12 months). Study population: Patients aged ≥18 years consulting a dermatologist or their GP for diagnosis, treatment or follow-up of a (pre)malignant skin lesion(s).
Detailed Description: See protocol
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Department of Dermatology, Ghent University Hospital, Ghent, , Belgium
MC Rotterdam Department of Dermatology, Rotterdam, , Netherlands
Contact Details
Name: Lieve Hoorens, MD, PhD
Affiliation: Ghent University Hospital, Department of Dermatology
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
